While only 3% of patients experienced hepatitis enzyme elevation and 0.85% of patients experienced treatment-related hepatitis among other cancer types [194], 13.7% of HCC patients treated with anti-PD-1 monotherapy experienced hepatitis enzyme elevation of any grade [195]. Here, PDCD1 is linked to hepatocellular carcinoma.